Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy

Trial Profile

A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 21 Jun 2020 Results of long-term follow-up of 3.5 years assessing safety and efficacy outcomes presented at the 25th Congress of the European Haematology Association
    • 21 Jun 2020 Results of an analysis (n=197, data cut-off date: Aug 2018), describing the rapidity and likelihood of response to Venetoclax treatments, and its associated characteristics, in older patients with newly diagnosed acute myeloid leukemia using data from two open-label trials (NCT02203773 and NCT02287233), were presented at the 25th Congress of the European Haematology Association.
    • 31 May 2020 Results (n=197: data cutoff date: Aug 2018) of an analysis from two clinical studies: NCT02203773 and NCT02287233 assessing rapidity and likelihood of response to Venetoclax treatments presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top